Benzinga

Benzinga

Benzinga

sábado, agosto 29

ADC Therapeutics SA

ADCTNYSE
Trade with Public
Trade with Public
$1.14
0.021.79%
al cierre: Aug 28, 5:00 PM EST
$1.12
-0.0198-1.74%
After hour: 7:21 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

ADC Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for ADC Therapeutics (ADCT).

Price Target Range — 13 Quarters

Analyst Consensus — 6 Analysts

3Buy
3Hold
Consensus RatingOverweight# Analysts6Avg. Consensus PT$6Upside to Avg. PT+413.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 17, 2026GuggenheimMichael SchmidtPT CutBuy$10→$5
Jun 8, 2026HC Wainwright & Co.Robert BurnsDowngradeBuy→Neutral—
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5

Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $10 to $5.
Benzinga Newsdesk

This ADC Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Monday

Top Wall Street analysts changed outlook on top names. ADCT downgraded See analysts' views.
Avi Kapoor

PRO
HC Wainwright & Co. Downgrades ADC Therapeutics to Neutral

HC Wainwright & Co. analyst Robert Burns downgrades ADC Therapeutics (NYSE:ADCT) from Buy to Neutral.
Benzinga Newsdesk

PRO
RBC Capital Downgrades ADC Therapeutics to Sector Perform, Lowers Price Target to $2

RBC Capital analyst Leonid Timashev downgrades ADC Therapeutics (NYSE:ADCT) from Outperform to Sector Perform and lowers the price target from $6 to $2.
Benzinga Newsdesk

PRO
RBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $6 Price Target

RBC Capital analyst Leonid Timashev reiterates ADC Therapeutics (NYSE:ADCT) with a Outperform and maintains $6 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates ADC Therapeutics (NYSE:ADCT) with a Buy and maintains $8 price target.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved